Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05435846 | Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation | terminated | Phase 1 | 3 | Collin BlakelyOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT02309892 | A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC | terminated | Phase 1 | 14 | Helix BioPharma CorporationINDUSTRY | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06288646 |
| Using Infrared Spectroscopy to Analyze Volatile Organic Compounds (VOCs) in the Breath of Patients With Lung Cancer |
| terminated |
| — |
| 12 |
| Breathe BioMedical IncINDUSTRY |
| 1 |
| May 31, 2024 |
| clinicaltrials |
| NCT04718610 | Heart Rate Variability, Vagus Nerve and Cancer | terminated | N/A | 25 | Centre Hospitalier Henri Duffaut - AvignonOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT02695680 | Lung SBRT Motion Management (GCC 1619) | terminated | — | 40 | University of Maryland, BaltimoreOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05790226 | Sentry Study: Raman Spectroscopy on Ex Vivo Lungs | terminated | N/A | 9 | University Health Network, TorontoOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT02635061 | Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer | terminated | Phase 1 | 17 | CelgeneINDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT05493501 | Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer | terminated | Phase 3 | 8 | EQRx International, Inc.INDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT04476797 | Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC(GRECO-1) | terminated | Phase 1 / Phase 2 | 47 | Galera Therapeutics, Inc.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT04211922 | Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | terminated | Phase 2 | 4 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT01898156 | Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer | terminated | Phase 1 / Phase 2 | 37 | Kyowa Kirin Korea Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | terminated | Phase 1 / Phase 2 | 1 | iOx TherapeuticsINDUSTRY | 3 | Apr 24, 2024 | clinicaltrials |
| NCT02954991 | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer | terminated | Phase 2 | 161 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04772053 | Molecular Disease Characterization Initiative (MDCI) | terminated | Phase 2 | 6 | GlaxoSmithKlineINDUSTRY | 2 | Apr 19, 2024 | clinicaltrials |
| NCT04027946 | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04925947 | A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02920996 | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 1 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03472560 | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) | terminated | Phase 2 | 61 | PfizerINDUSTRY | 8 | Apr 9, 2024 | clinicaltrials |
| NCT03400748 | ANET Electrosurgery Applicator Pilot Evaluation Study | terminated | N/A | 6 | Olympus Corporation of the AmericasINDUSTRY | 2 | Apr 3, 2024 | clinicaltrials |
| NCT03866980 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer | terminated | Phase 3 | 164 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT00310232 | Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20) | terminated | Phase 3 | 70 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04610658 | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03699956 | RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer(REPLATINUM) | terminated | Phase 3 | 18 | EpicentRx, Inc.INDUSTRY | 1 | Mar 26, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b | terminated | Phase 1 | 31 | Mersana TherapeuticsINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04610684 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | terminated | Phase 2 | 3 | Jeffrey ClarkeOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations(SUMMIT) | terminated | Phase 2 | 582 | Puma Biotechnology, Inc.INDUSTRY | 13 | Mar 12, 2024 | clinicaltrials |
| NCT04469725 | KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma | terminated | Phase 2 | 95 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04923802 | Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)(MOTIVATION) | terminated | — | 13 | GeneCast Biotechnology Co., Ltd.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | terminated | Phase 1 | 35 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04352413 | A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy | terminated | Phase 2 | 45 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04816214 | Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy(GEOMETRY-E) | terminated | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 3 | Mar 5, 2024 | clinicaltrials |
| NCT02759679 | Canine-Assisted Profiling of Lung Cancer From Human Breath | terminated | N/A | 650 | Haukeland University HospitalOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03403361 | Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of Patients Treated With Proton or Photon Therapy | terminated | N/A | 36 | Washington University School of MedicineOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03257722 | Pembrolizumab + Idelalisib for Lung Cancer Study(PIL) | terminated | Phase 1 / Phase 2 | 4 | Asha NayakOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04491084 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy(FLT3) | terminated | Phase 1 / Phase 2 | 5 | Albert Einstein College of MedicineOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | terminated | Phase 2 | 35 | Verastem, Inc.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03818776 | Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC | terminated | Early Phase 1 | 7 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT05408871 | Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases | terminated | Phase 1 | 7 | Yale UniversityOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT02654587 | OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure(ATALANTE-1) | terminated | Phase 3 | 219 | OSE ImmunotherapeuticsINDUSTRY | 10 | Feb 2, 2024 | clinicaltrials |
| NCT04676386 | Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy(BEACON-LUNG) | terminated | — | 29 | Addario Lung Cancer Medical InstituteOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | terminated | Phase 1 / Phase 2 | 26 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT00617656 | Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma(BREC) | terminated | Phase 3 | 382 | Spanish Lung Cancer GroupOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05176925 | Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC | terminated | Phase 2 | 5 | Fudan UniversityOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03966807 | Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting for Actively Smoking Family Members | terminated | — | 4 | Indiana UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2024source: clinicaltrials